Sandoz
Sandoz, a division of Novartis, is a global leader in the pharmaceutical industry, headquartered in Switzerland (CH). Founded in 1886, Sandoz has established itself as a pioneer in generic and biosimilar medicines, focusing on high-quality, affordable healthcare solutions. With a strong presence in Europe, North America, and emerging markets, the company is dedicated to improving patient access to essential medications. Sandoz's core offerings include a diverse range of generic pharmaceuticals, biosimilars, and over-the-counter products, distinguished by their rigorous quality standards and innovative approaches. The company has achieved significant milestones, including the launch of several groundbreaking biosimilars, solidifying its position as a trusted partner in the healthcare sector. With a commitment to sustainability and patient-centric solutions, Sandoz continues to shape the future of medicine.
DitchCarbon Score
How does Sandoz's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sandoz's score of 71 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sandoz's reported carbon emissions
In 2024, Sandoz reported total carbon emissions of approximately 1,988,500,000 kg CO2e. This includes Scope 1 emissions of about 82,100,000 kg CO2e, Scope 2 emissions of approximately 157,600,000 kg CO2e, and significant Scope 3 emissions totalling around 1,748,800,000 kg CO2e. The previous year, 2023, saw total emissions of about 2,260,100,000 kg CO2e, with Scope 1 at approximately 86,200,000 kg CO2e and Scope 2 at around 122,300,000 kg CO2e. Sandoz has set ambitious climate commitments, aiming to reduce its Scope 1 emissions by 30% from a 2020 baseline by 2030. Additionally, the company targets near-zero Scope 1 and Scope 2 emissions by 2025. These commitments reflect a proactive approach to climate action within the pharmaceutical sector, aligning with industry standards for sustainability. The company is also working towards achieving net-zero emissions by 2050, demonstrating a long-term commitment to reducing its carbon footprint. All emissions data is sourced directly from Sandoz Group AG, with no cascaded data from parent organizations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 75,620,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 158,430,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sandoz is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
